Vinpocetine is a drug that improves metabolism and blood circulation in the brain.
Release form and composition
Vinpocetine tablets are made, the active component of which is Vinpocetine (5 mg per 1 tablet). Auxiliary substances are magnesium stearate, talc, low molecular weight cellulose, lactose.
Also released solution Vinpocetine containing in 1 ml of 5 mg of vinpocetine. Additional components are ascorbic acid, tartaric acid, sorbitol, water for injection, sodium metabisulfite, benzyl alcohol.
Indications for use
According to the instructions, Vinpocetine is indicated for use in the following cases:
- Acute and chronic forms of cerebral circulatory failure, including transient ischemic attacks, residual and acute stages of stroke, encephalopathy, dementia due to cerebral circulatory disorders, traumatic brain injury, atherosclerosis of cerebral vessels;
- Toxic or age-related vascular hearing disorders, labyrinth etiology dizziness, Meniere's disease, tinnitus, cochleovestibular neuritis;
- Vascular pathologies of the retina or choroid, resulting from angiospasm, atherosclerosis, thrombosis;
- Degenerative changes in the macula resulting from angiospasm or atherosclerosis;
- Secondary glaucoma (due to vascular obturation);
- Vegetative symptoms of menopausal nature.
Children Vinpocetine prescribed for:
- Perinatal pathologies of the nervous system (the drug is able to stimulate cerebral blood circulation and positively affect areas where vascular changes are found);
- A sharp decrease in hearing;
- Treatment of the organs of vision (especially if the loss of vision is caused by vascular pathologies;
- Manic-depressive psychosis;
According to the instructions, Vinpocetine is contraindicated in the following cases:
- Pregnancy and breastfeeding;
- Coronary heart disease, especially in the severe stage;
- Hemorrhagic stroke in the acute stage;
- Hypersensitivity to the active or auxiliary components of the drug;
- Severe heart rhythm disorders.
Vinpocetine solution after hemorrhagic stroke is prescribed no earlier than 5 days after the reduction of acute events.
Dosing and Administration
If the disease is in an acute form, it is recommended to begin therapy with a solution of Vinpocetine, which is used intravenously.
The initial dosage is 20 mg, dissolved in 0.5-1 liter of infusion solution (per day). If the drug is well tolerated by the patient, an increase in the daily dose of 3-4 days to 1 mg per kilogram of weight is allowed.
The duration of Vinpocetine therapy averages 2 weeks.
After stabilization of the patient's condition, it is advisable to transfer it to the tablet form of Vinpocetine, while prescribing the drug in a dose of 5-10 mg three times a day.
The use of Vinpocetine can cause the following side effects:
- Lowering blood pressure;
- Inhibition of intraventricular conduction;
With parenteral administration of Vinpocetine, some patients noted a feeling of heat, flushing of the skin on the face, dizziness, thrombophlebitis at the injection site, nausea.
Currently, data on overdose of Vinpocetine has not been reported, however, if it has arisen, it is recommended to do a gastric lavage, take activated charcoal and carry out symptomatic treatment.
With the use of Vinpocetine in combination with heparin increases the likelihood of hemorrhagic complications.
Vinpocetine is prescribed with caution when:
- Angina pectoris;
- Unstable blood pressure;
- Reduced vascular tone.
In acute conditions, it is advisable to prescribe Vinpocetine therapy from a parenteral form, and after improving the patient's condition, switch to internal use. In chronic diseases, Vinpocetin is prescribed immediately by mouth.
Structural analogue of Vinpocetine is Cavinton.
Terms and conditions of storage
According to the instructions, Vinpocetine stored in a dark, dry, out of reach of children. The shelf life of both dosage forms is 5 years.